Comparative Pharmacology
Head-to-head clinical analysis: AEROSPORIN versus FML S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSPORIN versus FML S.
AEROSPORIN vs FML-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polymyxin B binds to the lipid A portion of bacterial lipopolysaccharides, disrupting the outer membrane permeability and causing bacterial cell death. It is primarily active against Gram-negative bacteria.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
Polymyxin B sulfate: 1.5-2.5 mg/kg/day intravenously divided every 12 hours, or 25,000-30,000 units/kg/day intramuscularly divided every 12 hours. Ophthalmic: 1-2 drops in affected eye every 4 hours. Topical: Apply to affected area 3-4 times daily.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min), necessitating dose adjustment.
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Primarily renal excretion of unchanged drug via glomerular filtration. Approximately 60-70% of an intravenous dose is recovered in urine within 24 hours; minimal biliary/fecal elimination (<5%).
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination